SEARCH

SEARCH BY CITATION

References

  • 1
    Pietrangelo A, Casalgrandi G, Quaglino D, et al. Duodenal ferritin synthesis in genetic hemochromatosis. Gastroenterology 1995; 108(1): 20817.
  • 2
    Powell LW, Yapp TR. Hemochromatosis. Clin Liver Dis 2000; 4(1): 21128, viii.
  • 3
    Cotler SJ, Bronner MP, Press RD, et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 1998; 29(2): 25762.
  • 4
    Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997; 112(3): 8828.
  • 5
    Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116(1): 193207.
  • 6
    Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4(2): 18398.
  • 7
    Ryan E, O'Keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998; 24(4): 42832.
  • 8
    Murphy S, Curran MD, McDougall N, Callender ME, O'Brien CJ, Middleton D. High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population — implications for haemochromatosis. Tissue Antigens 1998; 52(5): 4848.
  • 9
    Ryan F, Vaughan J. HFE mutation analysis in a normal Irish population. Br J Biomed Sci 2000; 57(4): 3156.
  • 10
    Byrnes V, Ryan E, Barrett S, Kenny P, Mayne P, Crowe J. Genetic hemochromatosis, a Celtic disease: is it now time for population screening? Genet Test 2001; 5(2): 12730.
  • 11
    Feder JN, Gnirke A, Thomas W, et al. A novel MHC class-1 like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996; 13(4): 399408.
  • 12
    Lucotte G, Champenois T, Semonin O. A rare case of a patient heterozygous for the hemochromatosis mutation C282Y and homozygous for H63D. Blood Cells Mol Dis 2001; 27(5): 8923.
  • 13
    Best LG, Harris PE, Spriggs EL. Hemochromatosis mutations C282Y and H63D in ‘cis’ phase. Clin Genet 2001; 60(1): 6872.
  • 14
    Mura C, Raguenes O, Férec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93: 25025.
  • 15
    Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. Uncommon mutations and polymorphisms in the haemochromatosis gene. Genet Test 2000; 4(2): 15161.
  • 16
    Beutler E, Griffin M, Gelbart T, West C. A previously undescribed nonsense mutation of the HFE gene. Clin Genet 2002; 61(1): 402.
  • 17
    Steiner M, Ocran K, Genschel J, et al. A homozygous HFE gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin. Gastroenterology 2002; 122(3): 78995.
  • 18
    Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis 2000; 26(2): 1638.
  • 19
    Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998; 114(5): 10038.
  • 20
    De Juan M, Reta A, Castiella J, Pozueta J, Prada A, Cuadrado E. HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum Genet 2001; 9(12): 9614.
  • 21
    Bauduer F, Scribans C, Renoux M, Borot N. Genetic hemochromatosis is a rare disease entity among French Basques: a center-based study from the general hospital of Basque County. Ann Hematol 2001; 80(8): 4723.
  • 22
    Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154(3): 193206.
  • 23
    Goochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002; 122(3): 64651.
  • 24
    Melis MA, Cau M, Deidda F, Barella S, Cao A, Galanello R. H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers. Haematologica 2002; 87(3): 2425.
  • 25
    Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116(1): 12734.
  • 26
    Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34(4): 2758.
  • 27
    Rivard S, Mura C, Simard H, et al. Mutation analysis in the HFE gene in patients with hereditary haemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Br J Haematol 2000; 108(4): 8548.
  • 28
    Proceedings of BioIron 2001 — World Congress on Iron Metabolism.J Clin Gastroenterol2002; 34:242273.
  • 29
    Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64(5): 138893.
  • 30
    Camaschella C, Roetto A, Cali C, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25(1): 145.
  • 31
    Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97(9): 255560.
  • 32
    Rivers CA, Barton JC, Acton RT. A rapid PCR-SSP assay for the hemochromatosis-associated Tyr250Stop mutation in the TFR2 gene. Genet Test 2001; 5(2): 1314.
  • 33
    Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28(3): 2134.
  • 34
    Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108(4): 61923.
  • 35
    Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326(2): 95100.
  • 36
    Kasvosve I, Gangaidzo IT, Gomo ZA, Gordeuk VR. African iron overload. Acta Clin Belg 2000; 55(2): 8893.
  • 37
    Anderson GJ, Powell LW. Haemochromatosis and control of intestinal iron absorption. Lancet 1999; 353(9170): 208990.
  • 38
    McKie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001; 291(5509): 17559.
  • 39
    Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388(6641): 4828.
  • 40
    Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403(6771): 77681.
  • 41
    Vulpe CD, Kuo YM, Murphy TL, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21(2): 1959.
  • 42
    Raja KB, Pountney D, Bomford A, et al. A duodenal mucosal abnormality in the reduction of Fe(iii) in patients with genetic haemochromatosis. Gut 1996; 38(5): 7659.
  • 43
    Zoller H, Pietrangelo A, Vogel W, Weiss G. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 1999; 353(9170): 21203.
  • 44
    Whittaker P, Skikne BS, Covell AM, et al. Duodenal iron proteins in idiopathic hemochromatosis. J Clin Invest 1989; 83(1): 2617.
  • 45
    Zoller H, Koch RO, Theurl I, et al. Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology 2001; 120(6): 14129.
  • 46
    Dupic F, Fruchon S, Bensaid M, et al. Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology 2002; 122(3): 74551.
  • 47
    Waheed A, Grubb JH, Zhou XY, et al. Regulation of transferring-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 2002; 99(5): 311722.
  • 48
    Rothenberg BE, Voland JR. β-2 knockout mice develop parenchymal iron overload: a putative role for class 1 genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci USA 1996; 93(4): 152934.
  • 49
    Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999; 94(1): 911.
  • 50
    Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997; 94(23): 123849.
  • 51
    Parkkila S, Parkkila AK, Waheed A, et al. Cell surface expression of HFE protein in epithelial cells, macrophages, and monocytes. Haematologica 2000; 85(4): 3405.
  • 52
    Salter-Cid L, Brunmark A, Li Y, et al. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci USA 1999; 96(10): 54349.
  • 53
    Roy CN, Penny DM, Feder JN, Enns CA. The hereditary hemochromatosis protein HFE specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 1999; 274(13): 90228.
  • 54
    Corsi B, Levi S, Cozzi A, et al. Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient prototype. FEBS Lett 1999; 460(1): 14952.
  • 55
    Riedel HD, Muckenthaler MU, Gehrke SG, et al. HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells. Blood 1999; 94(11): 391521.
  • 56
    Enns CA. Pumping iron: the strange partnership of the hemochromatosis protein, a class I MHC homolog, with the transferrin receptor. Traffic 2001; 2(3): 16774.
  • 57
    Crawford DH, Hickman PE. Screening for hemochromatosis. Hepatology 2000; 31(5): 11923.
  • 58
    Gambino R, Desvarieux E, Orth M, et al. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem 1997; 43(12): 240812.
  • 59
    McCullen MA, Crawford DH, Hickman PE. Screening for hemochromatosis. Clin Chim Acta 2002; 315(1–2): 16986.
  • 60
    Edwards CQ, Griffin LM, Gologar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318(21): 135562.
  • 61
    Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997; 127(2): 10510.
  • 62
    Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122: 2819.
  • 63
    Lio D, Balistreri CR, Colonna-Romano G, et al. Association between the MHC class 1 gene HFE polymorphisms and longevity: a study in Sicilian population. Genes Immun 2002; 3(1): 204.
  • 64
    Bathum L, Christiansen L, Nybo H, et al. Association of mutations in the hemochromatosis gene with shorter life expectancy. Arch Intern Med 2001; 161(20): 24414.
  • 65
    Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349(9048): 3213.
  • 66
    Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28(3): 4049.
  • 67
    Sampietro M, Piperno A, Lupica L, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998; 27(1): 1814.
  • 68
    Whitfield JB, Cullen LM, Jazwinska EC, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000; 66(4): 124658.
  • 69
    Pratiwi R, Fletcher LM, Pyper WR, et al. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. J Hepatol 1999; 31(1): 3946.
  • 70
    Van Vlierberghe H, Langlois M, Delanghe J, et al. Haptoglobin phenotype 2–2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001; 35(6): 70711.
  • 71
    Beutler E, Felitti VJ, Koziol JA, Ho NS, Gelbart T. Penetrance of 845?A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet 2002; 359(9302): 2118.
  • 72
    Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease. Medicine (Baltimore) 1955; 34: 381430.
  • 73
    MacDonald RA. Hemochromatosis and cirrhosis in different geographic areas. Am J Med Sci 1965; 249: 3646.
  • 74
    MacSween RN, Scott AR. Hepatic cirrhosis: a clinicopathological review of 520 cases. J Clin Pathol 1973; 26(12): 93642.
  • 75
    Olynyk JK, Cullen DJ, Aquila S, Rossi E, Summerville L, Powell LW. A population based study of the clinical expression of the haemochromatosis gene. N Engl J Med 1999; 341(10): 71824.
  • 76
    Beutler E, Felitti V, Gelbart BS, et al. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133(5): 32937.
  • 77
    Sanchez M, Bruguera M, Bosch J, Rodes J, Ballesta F, Oliva R. Prevalence of the Cys282Tyr and His63Asp HFE mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 1998; 29(5): 7258.
  • 78
    Willis G, Jennings BA, Goodman E, Fellows IW, Wimperis JZ. A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England. Blood Cells Mol Dis 1997; 23(2): 28891.
  • 79
    McDonnell SM, Hover A, Gloe D, Ou CY, Cogswell ME, Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999; 107(1): 307.
  • 80
    Adams PC. Population screening for hemochromatosis. Gut 2000; 46(3): 3013.
  • 81
    Adams PC, Brissot P, Powell LW. EASL International Consensus Conference on Hemochromatosis. J Hepatol 2000; 33(3): 485504.
  • 82
    El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132(4): 2619.
  • 83
    Tavill AS. Diagnosis and management of hemochromatosis. AASLD Practice Guidelines. Hepatology 2001; 33(5): 13218.
  • 84
    Tung BY, Kowdley KV. Clinical management of iron overload. Gastroenterol Clin North Am 1998; 27(3): 63754.
  • 85
    Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with hemochromatosis. J Path Bact 1962; 84: 5364.
  • 86
    Vautier G, Murray M, Olynyk JK. Hereditary haemochromatosis: detection and management. Med J Aust 2001; 175(8): 41821.
  • 87
    Moirand R, Mendler MH, Guyader D, et al. Revisiting biochemical expression in subjects heterozygous for hemochromatosis. Hepatology 1998; 28(Pt 2): 419A.
  • 88
    Wallace DF, Dooley JS, Walker AP. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 1999; 116(6): 140912.
  • 89
    Brittenham GM, Weiss G, Brissot P, et al. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Hematology (Am Soc Hematol Educ Program) 2000: 3950.
  • 90
    Kowdley KV, Trainer TD, Saltzman JR, et al. Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. Gastroenterology 1997; 113(4): 12707.
  • 91
    George DK, Ramm GA, Walker NI, Powell LW, Crawford DH. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. J Hepatol 1999; 31(1): 4752.
  • 92
    Guyader D, Gandon Y, Deugnier Y, et al. Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis. Gastroenterology 1999; 97(3): 73743.
  • 93
    Guyader D, Gandon Y, Roberts JY, et al. Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis. J Hepatol 1992; 15(3): 3048.
  • 94
    Stark DD. Hepatic iron overload: paramagnetic pathology. Radiology 1991; 179(2): 3335.
  • 95
    Kreeftenberg HG Jr, Mooyart EL, Huizenga JR, Sluiter WJ. Quantification of liver iron concentration with magnetic resonance imaging by combining T1-, T2-weighted spin echo sequences and a gradient echo sequence. Neth J Med 2000; 56: 1337.
  • 96
    Guyader D, Gandon Y, Sapey T, et al. Magnetic resonance iron-free nodules in genetic hemochromatosis. Am J Gastroenterol 1999; 94(4): 10836.
    Direct Link:
  • 97
    Kowdley KV, Hassanein T, Kaur S, et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transpl Surg 1995; 1(4): 23741.
  • 98
    Tung BY, Farrell FJ, McCashland TM, et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl Surg 1999; 5(5): 36974.
  • 99
    Powell LW. Hemochromatosis: the impact of early diagnosis and therapy. Gastroenterology 1996; 110(4): 13047.
  • 100
    Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transpl 2001; 7(8): 66372.
  • 101
    Kowdley KV, Brandhagen D, Gish R, et al. Survival after orthotopic liver transplant (OLT) among patients with hepatic iron overload: interim results from the National Hemochromatosis Transplant Registry (NHTR). Hepatology 2001; 34(4)(2): 236A.
  • 102
    Stuart KA, Fletcher LM, Clouston AD, et al. Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation. Hepatology 2000; 32(6): 12007.